UAE DNA Sequencing Market Market Report 2023 to 2030

UAE DNA Sequencing Market Analysis

$ 3999

UAE DNA Sequencing Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for DNA Sequencing is expanding as a result of advances in DNA Sequencing technology and increased applications in clinical diagnosis drug discovery. This is raising the demand for the market and is leading to increased investment in research & development for DNA Sequencing. Some of the key players in the global DNA Sequencing Market include Aglient Technologies, Illumina, Inc., Hoffmann-La Roche Ltd., QIAGEN, Perkin Elmer, Thermo Fisher Scientific, Macrogen, Inc., Bio-Rad Laboratories, Inc., Oxford Nanopore Technologies Ltd., Myriad Genetic, and Pacific Biosciences.

ID: IN10AEHS107 CATEGORY: Healthcare Services GEOGRAPHY: UAE AUTHOR: Dr. Nensi Savani

Buy Now

UAE DNA Sequencing Market Executive Summary

UAE DNA Sequencing Market is valued at around $29.2 Bn in 2022 and is projected to reach $74.3 Bn by 2030, exhibiting a CAGR of 12.4% during the forecast period 2023-2030.

DNA sequencing is used in the research and development of drugs. The nucleotides adenine (A), cytosine (C), guanine (G), and thymine (T) in a DNA molecule can be identified by sequencing it in a laboratory. The DNA from a sample that needs to be sequenced is produced, and the DNA is sequenced to get the necessary data, which is then thoroughly analysed. This method has many uses in the fields of virology, molecular biology, evolutionary biology, metagenomics, medicine, and forensic investigations.

The increased prevalence of Cancer has contributed to the growth of the global market for DNA Sequencing in recent years. Advances in sequencing technologies and the rising demand for precision medicine are also driving the market.

Firms like Agilent Technologies, Illumina, Inc., Hoffmann-La Roche Ltd., QIAGEN, Perkin Elmer, Thermo Fisher Scientific, Macrogen, Inc., Bio-Rad Laboratories, Inc., Oxford Nanopore Technologies Ltd., Myriad Genetic, and Pacific Biosciences, are some of the major players in the DNA Sequencing Market.

The discovery of DNA variants has been made possible by quick developments in bioinformatics and sequencing technologies. These developments also identify variations linked to a higher risk of disease. The efficacy of DNA sequencing in clinical diagnosis applications is increased by the widespread use of next-generation sequencing (NGS) and whole-genome sequencing (WGS), which enables the simultaneous testing of a wide variety of genes in a single diagnostic platform.

DNA sequencing, a highly accurate and high-throughput technique used for a range of applications including de novo assembly, WGS, and DNA resequencing, has caused a paradigm shift in proteomic and genomic research. As a result, this technology is easily used for research studies in many academic research centres.

Market Dynamics

Drivers of UAE DNA Sequencing Market:

Advancements in DNA Sequencing: The increased advancements in technology in DNA Sequencing have a huge impact on driving the market as it helps speed up the process and reduce the costs.

Increasing Application in Clinical Diagnosis: Applications for DNA sequencing can be found in diagnostics, forensics, personalised medicine, biomarkers, reproductive health, and other fields. The development of cancer diagnosis and treatments using DNA sequencing technology has significant potential in boosting the DNA Sequencing Market.

Growing Research & Development Initiatives: There has been a lot of investment in the research & development of DNA Sequencing for drug discovery and development which is propelling the market to grow.

Notable Deals in DNA Sequencing Market:

In 2023, Illumina Inc., a pharmaceutical company, and Nashville Biosciences LLC announced an agreement with Amgen, a biopharmaceutical company, for a whole-genome sequence of DNA samples; approximately 35,000 samples. This helped in accelerating therapeutic development through genomics.

In 2022, Element Biosciences, Inc., a developer of the revolutionary DNA sequencing platform, announced the launch of Avidity Cloudbreak Technology. The AVITI technology operates two random access flow cells for independent run starts, with AVITI Operating Software that features tunable read throughout for additional flexibility.

In 2022, PacBio announced the release of twp genome sequencing systems, the Revio long-read sequencing system and the Onso short-read sequencing system. Deep-learning methods are also integrated into Revio to detect DNA methylation from regular sequencing libraries.

In 2022, Perkin Elmer, Inc. a pharmaceutical company, announced the launch of the BioQule NGS Research System for delivering reliability for a wide variety of applications such as enabling the creation of high-quality NGS libraries that deliver highly reproducible results and genome analysis.

In 2022, NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced a seamless cloud-based workflow names GeoMx Digital Spatial Profiler. Spatial analysis of the entire transcriptome with proteome analytes can now be simplified using this integrated push-button walk planning tool.

Key players

Illumina, Inc. Thermo Fisher Scientific, Inc. BGI Middle East Eurofins Genomics Middle East Dubai Biotechnology and Research Park (DuBiotech) Falcon Genomics Zayed University Medgenome Labs Dubai Biogenix Labs Maktoum Foundation Genomics Centre

1. Executive Summary
1.1 Service Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Healthcare Services Market in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Services
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market Segmentations For UAE DNA Sequencing Market

By Product Type:

Instruments
Consumables
Services

By Sequencing Type:

Sanger Sequencing
Next-generation Sequencing
Third Generation DNA Sequencing

By Application:

Clinical Investigation
Oncology
Forensics & Agri-genomics
Reproductive Health
HLA Typing
Biomarkers
Cancer
Diagnostics
Personalized Medicine

By End-user:

Hospitals and Clinics
Clinical Research
Academics Institutions
Biotechnology & Pharmaceutical Companies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.